William Johnson offers extensive expertise to Cell One Partners in his role as the Managing Partner of Boler Biotech Consulting. He provides strategic research and analysis for investors and clients involved with early-stage biotechnology companies, advising management on business, market, financing, and regulatory trends that may impact these ventures. William's extensive experience includes sourcing, investigating, and assessing the scientific and market potential of new technologies and therapies. He excels in helping companies start up, guiding and overseeing transactional and project finances for early-stage portfolio ventures. His broad-based scientific and therapeutic background, with strong credentials in molecular biology, immunology, and bioinformatics, has proven invaluable in developing therapies targeting cancers, diabetes, arthritis, and neurological disorders.

​

In addition to his scientific expertise, William has significant business acumen. As a start-up equity partner, adviser to company leaders and boards, and due diligence leader, he understands what makes for the "right" technology. His distinguished research credentials include key roles at renowned organizations such as Novartis, Wyeth, EMD Millipore, the Broad Institute, and Mayo Clinic, where he has been instrumental in go/no-go technology and therapy pursuit decisions, identifying promising cellular targets for therapies, and validating success-critical laboratory results. William's ability to navigate the biotech and pharma landscape, identifying promising new technologies and companies from industry conferences, academic, and healthcare sources, underscores his value in driving innovation and success in the biotechnology sector.